A Study of AZD8233 in Participants With Dyslipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 119 participants.

Also called NCT04641299

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 119 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04641299
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Denmark, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04641299. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-28 (actual); primary completion 2021-07-20 (actual). Results posted on 2022-11-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of AZD8233 in Participants With Dyslipidemia
Condition
Dyslipidaemia
Intervention (Drug)
AZD8233
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04641299
Content hash
8844db0c5284c1fe73b36c22a5eab11fc088dd164952683b00f30dd17eb2bedf